Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil plus fruquintinib versus either agent alone for third-line unresectable metastatic colorectal cancer
ChiCTR2400088929Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trifluridine + tipiracil and fruquintinib in colorectal cancer (CRC) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400088929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088929.